TP53 Antibody (AMM00023)

Catalog#: AMM00023

• Size: 100ug

Human DU145

Human DU145

Human U2OS, PLKO

• Description of Target: Tumor protein p53 responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome
• Gene Symbol: TP53
• Alias Symbols: P53; LFS1; TRP53; FLJ92943; TP53
• Protein Accession#: NP_000537
• Nucleotide Accession#: NM_000546
• Swissprot Id: P04637
• Host: Mouse
• Protein Size (# AA): 393
• Molecular Weight: 53kDa
• Application: WB
• Product Format: Lyophilized powder
• Isotype: Mouse IgG
• Reconstitution and Storage: Add 100ul of distilled water. Final anti-TP53 antibody concentration is 1 mg/ml in PBS buffer. For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
• Key Reference: Khanna,K.K., et al., Nat. Genet. 20 (4), 398-400 (1998)

Customer Reviews for TP53 Antibody (AMM00023) tested with U20S, PLKO cells in Chromatin Immunoprecipitation

CAT#AMM00023
-submitted by:
Nick Barlev
University of Leicester

U20S (p53+) cells were treated with 0.5 uM Doxorubicin for 14 hrs to induce DNA damage and hence activate p53. In parallel, PLKO cells (U2OS cells with stable shRNA-mediated knockdown of p53) were treated similarly and were used as negative control. Thedata for p21 promoter were normalised to actin (control for non-specific binding of DNA to the antibodies).

Product Review:TP53 Antibody (AMM00023) in PLKO AND U2OS cells using ChIp Assays

Product Page Link: TP53 Antibody (AMM00023)

Data provided by: Dr. Barlev, University of Leicester

Figure 1. Binding of p53-specific antibodies to the p21 promoter. U20S (p53+) cells were treated with 0.5 uM Doxorubicin for 14 hrs to induce DNA damage and hence activate p53. In parallel, PLKO cells (U2OS cells with stable shRNA-mediated knockdown of p53) were treated similarly and were used as negative control. Thedata for p21 promoter were normalised to actin (control for non-specific binding of DNA to the antibodies).

Product Review: TP53 Antibody (AMM00023) in DU145 cells using Western Blot

Product Page for TP52 Antibody (AMM00023)

Data Provided by Dr. Andrei Gartel, University of Illinois at Chicago

DU145 cells were lysed in IP lysis buffer: 20 mM HEPES, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 100 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, 0.2 mM PMSF

Amount of Protein per well: 30 ug

Primary antibody conditions: 1:2000 in 5% milk/TBST buffer, overnight at 4°C

Secondary antibody conditions: 1 to 5000 in 5% milk/TBST buffer, 1 hour at room temperature